Journal article icon

Journal article

A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?

Abstract:

The first meningococcal vaccine with the potential to provide broad coverage against serogroup B disease has recently been approved for use in Europe. This vaccine, multi-component serogroup B vaccine (4CMenB), contains recombinant proteins and outer membrane vesicles, and has been extensively studied in clinical trials involving over 7500 adults, children and infants. As well as demonstrating immunogenicity against a range of serogroup B meningococcal strains, these trials have also demonstr...

Expand abstract

Actions


Access Document


Authors


Martin, NG More by this author
Journal:
Expert review of vaccines
Volume:
12
Issue:
8
Pages:
837-858
Publication date:
2013-08-05
DOI:
EISSN:
1744-8395
ISSN:
1476-0584
URN:
uuid:ecad5297-5eb6-4f11-9798-88064e06dd9c
Source identifiers:
440487
Local pid:
pubs:440487

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP